OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting	251
Interplay between platelets and coagulation	147
Targeting MCL-1 in hematologic malignancies: Rationale and progress	130
Coagulation and anticoagulation in COVID-19	122
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system	116
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes	106
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	96
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents	81
The looming storm: Blood and cytokines in COVID-19	65
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	62
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	58
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map	52
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	51
A review of FLT3 inhibitors in acute myeloid leukemia	50
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	50
Role of inflammation in the biology of myeloproliferative neoplasms	49
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	49
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions	45
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation	44
Illness and prognostic understanding in patients with hematologic malignancies	42
Current state and next-generation CAR-T cells in multiple myeloma	39
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	39
Discussing investigational AAV gene therapy with hemophilia patients: A guide	38
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies	38
Inherited thrombocytopenias: an updated guide for clinicians	37

Current management strategies for polycythemia vera and essential thrombocythemia	36
Current and emerging strategies for management of myelodysplastic syndromes	34
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer	32
Second primary malignancies in multiple myeloma: A review	30
IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly	29
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation	28
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	28
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	27
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models	25
Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management	24
CLL update 2022: A continuing evolution in care	24
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	24
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma	23
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	22
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?	22
Complement activation in COVID-19 and targeted therapeutic options: A scoping review	22
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness	22
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways	22
The emerging role of red blood cells in cytokine signalling and modulating immune cells	22
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?	21
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations	21
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	21
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions	21
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	21
Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential	20
Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations	20
Artificial intelligence in hematological diagnostics: Game changer or gadget?	20
It takes two to thrombosis: Hemolysis and complement	20
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	20
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	20
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation	20
A review on how to do hematology consults during COVID-19 pandemic	19
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	19
Immune thrombocytopenia: A review of upfront treatment strategies	19
Metabolic regulation of the bone marrow microenvironment in leukemia	19
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	19
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations	18
Magnesium: The overlooked electrolyte in blood cancers?	18
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression	18
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	18
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	18
AML and the art of remission maintenance	18
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity	18
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia	17
Revisiting Richter transformation in the era of novel CLL agents	17
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	17
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics	17
Germline genetic factors in the pathogenesis of myeloproliferative neoplasms	16
Peripheral neuropathy in hematologic malignancies – Past, present and future	16
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation	16

A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management	16
Advances in the management of TTP	15
Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review	15
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia	15
Deciphering the messages carried by extracellular vesicles in hematological malignancies	15
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap	15